Fideliomed

A central element of Fideliomed’s value proposition is the Online Anemia Clinic, a SaaS (Software as a Service) platform scheduled for launch in 2026. The solution enables physicians, pharmacies, home-care providers, and facilities located in remote areas to carry out anemia screening, monitoring, and management through a single operational workflow, reducing fragmentation in care pathways and the need for repeated specialist visits. The platform will integrate with a patented diagnostic device for capillary blood analysis, combining AI, clinical data, and proprietary hardware to deliver scalable and widely accessible health pathways while maintaining high levels of accuracy and specialist oversight. The Foundation’s investment aims to support Fideliomed’s growth phase, accompanying the start-up toward the commercialization of the platform and the subsequent integration of the medical device. The developed technology makes it possible to anticipate diagnosis, reduce preventable complications, and improve the management of vulnerable patients — including pregnant women, children, the elderly, and individuals with chronic conditions — while also contributing to the reduction of hospital admissions and readmissions linked to late diagnoses or fragmented care pathways. Through its activities, Fideliomed actively contributes to the achievement of the United Nations Sustainable Development Goals, particularly SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation and Infrastructure), and SDG 10 (Reduced Inequalities), by promoting a more equitable, preventive, and efficient model for access to diagnostics and specialist care.